HAE241220P60000
- 0.91
- 0.000.00%
Haemonetics Newsroom
ABT Stock Benefits From First Patient Procedures With TAVI System
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), Alcon (ALC)
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
International Expansion Supports BSX Stock Amid Macroeconomic Woes
Haemonetics Corporation's (NYSE:HAE) P/E Is On The Mark
Express News | Haemonetics Q2 Adjusted Free Cash Flow USD 49 Million
Express News | Haemonetics Q2 EPS USD 0.66
Express News | Haemonetics Q2 Adjusted EPS USD 1.12 Vs. IBES Estimate USD 1.07
Express News | Haemonetics Q2 Revenue USD 346 Million Vs. IBES Estimate USD 342.6 Million
Here's Why You Should Add OMCL Stock to Your Portfolio Now
Needham Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $112
Strategic Investment and Growth Potential Drive Buy Rating for Haemonetics
Haemonetics Management to Meet Virtually With BTIG
Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
Raymond James Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $108 to $125
Haemonetics Second Quarter 2025 Earnings: EPS Misses Expectations
Haemonetics Corporation (HAE) Q2 2025 Earnings Call Transcript Summary